Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLAIR vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular c AMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Treatment of chronic obstructive pulmonary disease (COPD)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/m L. Maintenance: 400-600 mg/day in divided doses.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by N-demethylation and oxidation. Approximately 10% excreted unchanged in urine.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
40% bound, primarily to albumin
65% bound to albumin
0.45 L/kg; approximates total body water; higher in infants
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral: 96% (immediate release); sustained release: 80-100%
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
GFR < 30 m L/min: reduce dose by 50% and monitor serum levels. GFR 30-50 m L/min: reduce dose by 25%.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class B: reduce dose by 50%. Class C: reduce dose by 75% or use alternative.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Children 1-9 years: starting dose 10-16 mg/kg/day orally in divided doses every 4-6 hours; max 600 mg/day. Children 9-16 years: 10-16 mg/kg/day; max 800 mg/day. Adjust based on serum levels (5-15 mcg/m L).
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Start at lower end of dosing range (300 mg/day), titrate slowly with close monitoring of serum levels due to decreased clearance.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA black box warning.
No FDA black box warning.
Narrow therapeutic index; monitor serum theophylline levels to avoid toxicity.,Risk of serious cardiovascular events (e.g., arrhythmias, seizures) at high serum concentrations.,May exacerbate peptic ulcer disease.,Use caution in patients with hypoxemia, hypertension, or heart failure.,Drug interactions: cimetidine, fluoroquinolones, macrolides, and other CYP450 inhibitors increase levels; phenytoin, rifampin, and smoking decrease levels.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or any component of the formulation,Active peptic ulcer disease,Uncontrolled seizure disorders
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Dietary changes that affect CYP1A2 activity alter theophylline clearance. High-protein, low-carbohydrate diets increase clearance; high-carbohydrate, low-protein diets decrease clearance. Charcoal-broiled meats and cruciferous vegetables (e.g., broccoli, cabbage) induce metabolism, reducing efficacy. Caffeine-containing foods and beverages can potentiate toxicity and should be limited. Consistent dietary habits are critical to maintain stable serum levels.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Theophylline (active ingredient in THEOLAIR) is classified as FDA Pregnancy Category C. Human data do not indicate a major teratogenic risk; however, a small increased risk of congenital anomalies cannot be excluded. First trimester: No consistent evidence of teratogenicity; some studies suggest possible association with cardiac defects. Second/third trimester: May cause fetal tachycardia, irritability, and jitteriness due to transplacental passage; neonatal withdrawal symptoms possible. Avoid use near term if possible.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.72. Concentrations in milk are about 60% of maternal serum. Breastfeeding is generally considered safe if maternal levels are therapeutic; however, irritability and insomnia in infants have been reported. Monitor infant for signs of caffeine-like effects. Use with caution, especially in preterm infants.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Pregnancy may decrease theophylline clearance by about 30% due to reduced protein binding and increased volume of distribution, but changes can vary. Dose adjustments should be guided by serum level monitoring. Typical starting dose: 400 mg/day oral, titrated to levels 5–15 mcg/m L. Increased doses may be needed in later pregnancy due to altered pharmacokinetics. Postpartum, clearance may increase, requiring dose reduction.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Theophylline (THEOLAIR) has a narrow therapeutic index (5-15 mg/L). Monitor serum levels due to inter- and intra-patient variability. Coadministration with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) or inducers (e.g., phenytoin, smoking) requires dose adjustments. Use with caution in patients with hepatic impairment, congestive heart failure, or fever, as clearance is reduced.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not double the dose if missed.,Avoid changes in smoking habits, diet, or new medications without consulting your doctor.,Report nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Do not consume large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects.,Maintain consistent intake of high-protein or low-protein diets.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLAIR vs AEROLATE, answered by our medical review team.
THEOLAIR is a Bronchodilator that works by Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular c AMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLAIR and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLAIR is: Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/m L. Maintenance: 400-600 mg/day in divided doses.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLAIR and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLAIR is classified as Category C. Theophylline (active ingredient in THEOLAIR) is classified as FDA Pregnancy Category C. Human data do not indicate a major teratogenic risk; however, a small increased risk of cong. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.